Literature DB >> 7060015

Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery.

G Poste, C Bucana, A Raz, P Bugelski, R Kirsh, I J Fidler.   

Abstract

Functional and ultrastructural studies of liposomes injected i.v. into inbred C57BL/6N mice were performed to determine whether free liposomes can traverse capillaries. In the liver and spleen, organs with discontinuous (sinusoidal) capillaries, ultrastructural and cell fractionation studies revealed that small (300- to 800-A diameter), sonicated, unilamellar liposomes were more efficient in penetrating liver sinusoids to interact with hepatocytes than were large (0.5- to 10-micrometers) multilamellar liposomes. Ultrastructural studies of the behavior of liposomes in the continuous capillaries of the lungs revealed that circulating phagocytic cells engulf the liposomes in the capillaries. Transcapillary migration of free liposomes was not observed. We conclude that free liposomes are unable to extravasate to reach the alveoli for subsequent engulfment by alveolar macrophages. Instead, liposomes in the lung capillaries are engulfed by circulating blood phagocytes which subsequently migrate to the alveoli to become alveolar macrophages. Experiments on the recruitment of blood monocytes into the lungs subjected to whole- or partial-body X-radiation confirmed that transfer of i.v.-injected liposomes to the alveolar compartment was mediated by blood monocytes. The inability of liposomes to escape from continuous capillaries and their rapid uptake by circulating and fixed phagocytic cells calls into question the feasibility of using liposomes to "target" drugs to cells in extravascular tissues.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7060015

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Imaging, autoradiography, and biodistribution of (188)Re-labeled PEGylated nanoliposome in orthotopic glioma bearing rat model.

Authors:  Feng-Yun J Huang; Te-Wei Lee; Chih-Hao K Kao; Chih-Hsien Chang; Xiaoning Zhang; Wan-Yu Lee; Wan-Jou Chen; Shu-Chi Wang; Jem-Mau Lo
Journal:  Cancer Biother Radiopharm       Date:  2011-12       Impact factor: 3.099

2.  The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.

Authors:  Shan Gao; Frederik Dagnaes-Hansen; Ebbe Juel Bech Nielsen; Jesper Wengel; Flemming Besenbacher; Kenneth Alan Howard; Jørgen Kjems
Journal:  Mol Ther       Date:  2009-04-28       Impact factor: 11.454

3.  Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model.

Authors:  Robert D Arnold; Donald E Mager; Jeanine E Slack; Robert M Straubinger
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

4.  Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide.

Authors:  P Brodt; J Blore; N C Phillips; J S Munzer; J D Rioux
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 5.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

Review 6.  The evolving landscape of drug products containing nanomaterials in the United States.

Authors:  Sheetal R D'Mello; Celia N Cruz; Mei-Ling Chen; Mamta Kapoor; Sau L Lee; Katherine M Tyner
Journal:  Nat Nanotechnol       Date:  2017-04-24       Impact factor: 39.213

Review 7.  Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.

Authors:  Alberto Gabizon; Hilary Shmeeda; Yechezkel Barenholz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Identification and characterization of a monoclonal antibody to an antigen expressed on activated macrophages.

Authors:  T P Koestler; D Rieman; K Muirhead; R G Greig; G Poste
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

9.  Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II).

Authors:  J Lautersztain; R Perez-Soler; A R Khokhar; R A Newman; G Lopez-Berestein
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Pegylated liposomal doxorubicin in ovarian cancer.

Authors:  Robert Strother; Daniela Matei
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.